Victoria P. Werth, MD, discusses how litifilimab’s 52-week AMETHYST findings inform treatment expectations and timely reassessment of persistent cutaneous lupus symptoms.
|Articles|July 14, 2016
Another Insurer Withdrawals from ACA Marketplaces
Author(s)Laurie Toich, Assistant Editor
New Mexican insurer Presbyterian Health Plan announces withdrawal from their ACA marketplace.
Advertisement
Presbyterian Health Plan is the latest insurer to drop out of the Affordable Care Act (ACA) health insurance exchange in New Mexico.
Like many other insurers, they found that enrollees were visiting physicians more and had higher costs than expected. The insurer is predicting a loss of $26 million this year, according to the
Presbyterian has 26,000 ACA enrollees, and approximately 10,000 individuals who receive subsidies will need to find new coverage. Approximately 70% of enrollees in any of the New Mexico plans receive subsidies that reduce monthly premiums by more than half, the Santa Fe New Mexican reported.
Like other insurers who have also withdrawn from marketplaces, these individuals will be covered until the end of the year. The insurers originally put in a request to increase premiums by 35%, but later decided to withdraw from the marketplace plans.
They will continue to offer plans to Medicare, Medicaid, and employers instead, and has proposed a smaller premium increase.
Advertisement
Related to this article
In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses why meaningful improvement extends beyond skin clearance and how response timing affects patients with difficult-to-control disease.
Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.
As psychedelic therapies advance through clinical development, pharmacists should prepare for potential roles in their safe, evidence-based integration into patient care.
How oncology pharmacy leaders fight burnout with stay surveys, smarter schedules, and recognition—building resilient teams through loss and turnover.
At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.
In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
Advertisement
Advertisement
Trending on Pharmacy Times
1
Preparing Pharmacists for Psychedelic Medicine
2
Pneumonic Plague: What Pharmacists Need to Know About Treatment
3
Beyond Skin Clearance: What Litifilimab Could Mean for Cutaneous Lupus Care
4
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
5